KOICHI TAKAHASHI to Risk Factors
This is a "connection" page, showing publications KOICHI TAKAHASHI has written about Risk Factors.
Connection Strength
0.156
-
Germline polymorphisms and the risk of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2019 03; 32(1):24-30.
Score: 0.051
-
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol. 2017 01; 18(1):100-111.
Score: 0.044
-
Clonal Hematopoiesis Risk Score and All-Cause and Cardiovascular Mortality in Older Adults. JAMA Netw Open. 2024 Jan 02; 7(1):e2351927.
Score: 0.018
-
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality. Leukemia. 2020 11; 34(11):2914-2924.
Score: 0.014
-
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Int J Hematol. 2019 May; 109(5):545-552.
Score: 0.013
-
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol. 2013 Oct; 88(10):831-7.
Score: 0.009
-
Heparin-induced thrombocytopenia: analysis of risk factors in medical inpatients. Br J Haematol. 2011 Aug; 154(3):373-7.
Score: 0.007